Beacon Biosignals
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $124M
Investors
- 15
About Beacon Biosignals
Beacon Biosignals, Inc.Beacon Biosignals, Inc. was founded in 2019 by co-founder Jacob Donoghue and Jarrett Revels, and headquartered in Boston, US. The company specializes in neurotechnology that leverages AI to enhance the treatment of neurological and psychiatric disorders. In April 2026, Beacon Biosignals, Inc. Beacon Biosignals specializes in AI-powered neurotechnology aimed at enhancing the understanding and treatment of neurological and psychiatric disorders. Their core offerings include an FDA-cleared headband that captures high-fidelity electroencephalography (EEG) data both at home and in clinical settings. This technology enables the collection and analysis of sleep data to identify novel biomarkers, assess treatment effects, and stratify patient populations effectively. Beacon’s services cater to a broad range of indications, addressing psychiatric disorders like major depressive disorder, schizophrenia, and bipolar disorder, as well as primary and secondary sleep disorders.The revenue model of Beacon Biosignals primarily revolves around B2B transactions, focusing on partnerships with pharmaceutical companies and clinical research organizations. Clients engage with Beacon to access its platform and services, which include analytics software and support from the Clinical Study Operations and Scientific Services teams. The company may employ a subscription-based pricing structure for ongoing access to its technology and data analytics capabilities. Additionally, revenue could be generated through specific project-based agreements, where clients pay for tailored services related to clinical trial management and reporting. Such transactions involve detailed agreements on data utilization and analysis, enabling clients to derive meaningful insights from the EEG data collected during their studies.
Who invested in Beacon Biosignals
15 investors across 4 rounds
See all investors in Beacon Biosignals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beacon Biosignals
Who invested in Beacon Biosignals?
Beacon Biosignals has 15 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beacon Biosignals raised?
Beacon Biosignals has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Beacon Biosignals last raise money?
Beacon Biosignals's most recent round on record is a Series B, in Apr 2026.
What does Beacon Biosignals do?
Beacon Biosignals is a software company.
Where is Beacon Biosignals headquartered?
Beacon Biosignals is headquartered in Boston, US.
Which VCs invest in companies like Beacon Biosignals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back software companies at Beacon Biosignals's stage. Their profiles are linked below.
VCs backing software startups at Series B
Raising like Beacon Biosignals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.